Multiple sclerosis trials in Romania

In Romania 9 Also abroad 506

9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Where
Brasov, Constanța, Târgu Mureş
Age
18 years to 60 years
People
705 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07067463 · EU 2025-524316-11-00
Phase 3Taking people
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Where
Constanța, Radauti, jud. Suceava
Age
18 years to 60 years
People
990 worldwide
Run by
Zenas BioPharma (USA), LLC
See details and how to joinNCT07299019 · EU 2025-524322-18-00
Phase 3Taking people
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
Where
Campulung
Age
18 years to 64 years
People
386 worldwide
Run by
Sanofi-Aventis Recherche & Developpement
See details and how to join2023-504358-36-00 · EU 2023-504358-36-00
Phase 2Taking people
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
Where
Cluj-Napoca
Age
18 years to 64 years
People
230 worldwide
Run by
Immunic AG
See details and how to joinNCT05054140 · EU 2024-514617-35-00
Phase 3Taking people
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
Where
Bucharest, Cluj-Napoca
Age
18 years to 64 years
People
125 worldwide
Run by
Amgen Inc.
See details and how to join2024-512914-16-00 · EU 2024-512914-16-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Where
Bucharest, Campulung Muscel, Constanța
Age
18 years to 65 years
People
1,275 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07225504
Phase 3Taking people
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Where
Bucharest
Age
Up to 17 years
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-511686-11-00 · EU 2024-511686-11-00
Phase 3Taking people
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Where
Bucharest
Age
10 years to 17 years
People
194 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06408259 · EU 2022-501332-42-00
Phase 3Taking people
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
Where
Bucharest, Campulung, Constanța
Age
18 years and over
People
677 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521546-23-00 · EU 2025-521546-23-00